Life Sciences

  • August 26, 2025

    Ex-Genentech Worker Urges 9th Circ. To Revive ERISA Suit

    Counsel for a former Genentech employee urged the Ninth Circuit at a hearing Tuesday to revive his client's proposed class action alleging the biotechnology company kept unwise investment options in its 401(k) plan for years, saying the case is "vastly different" from one the lower court cited when tossing the suit.

  • August 26, 2025

    Healthcare Deals This Week: AbbVie, Royalty Pharma, BeOne

    A few notable transactions marked healthcare dealmaking this past week, as companies bought up assets and inked contracts to expand their portfolios. Here, Law360 breaks down those deals and others from the past week.

  • August 26, 2025

    AI Copyright Licensing Is Helping To Fuel Tech's Evolution

    While courts wrestle with fair use questions around artificial intelligence training, legal experts say the growing number of licensing deals between tech companies and copyright owners is setting market norms for accessing the troves of content needed across rapidly evolving AI applications.

  • August 26, 2025

    Fed. Circ. Backs Original Filer In First-Ever Derivation Ruling

    The Federal Circuit clarified the differences between derivation and interference proceedings on Tuesday while affirming that a podiatrist didn't derive his wound treatment patent application from a former collaborator.

  • August 26, 2025

    Mich. AG Lambasts UMich For Halting Trans Youth Care

    Michigan's attorney general publicly warned the University of Michigan Tuesday that her office was "considering all of our options" after the university's hospital system said it would cease providing gender-affirming care to minors under pressure from the Trump administration. 

  • August 26, 2025

    Blacklist Suit Blocked By Illegal Biz Ties, Justices Told

    LegitScript has asked the U.S. Supreme Court to intervene against the Ninth Circuit's decision to make it face PharmacyChecker.com's antitrust blacklisting claims, arguing the lower court rulings wrongly allow PharmacyChecker to sue to protect a business focused on facilitating the illegal importation of drugs.

  • August 26, 2025

    King & Spalding Hires Former CMS Litigation Leader In DC

    The former deputy associate general counsel for litigation in the general counsel's office at the Centers for Medicare & Medicaid Services has joined King & Spalding LLP as a partner in Washington, D.C., the firm announced Tuesday.

  • August 26, 2025

    Frier Levitt Adds FDA Regulation Specialist Duo

    New Jersey-based national healthcare law boutique Frier Levitt added a partner and senior counsel pair from a life science law boutique this week to expand its expertise in Food and Drug Administration regulation and compliance and the cannabis and hemp industries.

  • August 26, 2025

    Foley Hoag Adds Healthcare Co-Leader From Manatt

    Foley Hoag LLP has hired the former president and CEO of the National Hospice and Palliative Care Organization as the new co-chair of its healthcare department.

  • August 25, 2025

    Eli Lilly Settles Feud With Clinics Over TM Infringement

    Eli Lilly & Co. has come to terms with two clinics that it sued in Washington federal court for trademark infringement after accusing them of tricking customers into thinking they were buying brand name versions of weight loss medications Mounjaro and Zepbound.

  • August 25, 2025

    Medical Device Co. Eyes $400M Raise For Solana Treasury

    A medical device company on Monday announced its plans to raise $400 million through a private placement offering to build a crypto treasury composed primarily of the Solana blockchain token SOL.

  • August 25, 2025

    Fed. Circ. Overbroad In Hip Joint Implant Suit, High Court Told

    A German medical supplier wants the U.S. Supreme Court to take up its appeal of the Federal Circuit's refusal to revive its trade dress protections for the color pink in a hip joint implant part, saying a circuit split warrants the justices' review.

  • August 25, 2025

    Sanofi Escapes Out-Of-State Claims In Conn. Zantac Lawsuit

    Sanofi-Aventis U.S. LLC has escaped negligent design claims filed in Connecticut by hundreds of buyers who did not purchase or consume the heartburn drug Zantac in the Constitution State and who never developed cancer or suffered related harms within its borders.

  • August 25, 2025

    Radiology Co. Wants Arbitral Award Nixed Over 'Legal Fiction'

    A Georgia-based radiology provider has urged a federal court to nix an arbitral award rejecting its $2 million fraud claim against an Indian company, saying the arbitrator "manufactured a legal fiction out of whole cloth."

  • August 25, 2025

    Fired CTA Worker Faced Bias Over Vax Refusal, Jury Told

    A former Chicago Transit Authority electrician was unlawfully fired from his job after he refused to take the COVID-19 vaccine due to his Catholic faith, even if he also had medical and scientific concerns with the shot, an Illinois federal jury heard on Monday.

  • August 25, 2025

    Cooley, Latham Lead $360M ScPharmaceuticals Acquisition

    Cooley LLP-advised biopharmaceutical company MannKind on Monday unveiled plans to buy scPharmaceuticals, led by Latham & Watkins LLP, for up to $360 million.

  • August 25, 2025

    Generic-Drugs Group Asks 9th Circ. To Nix Pay-For-Delay Law

    A trade group for generic drugmakers urged the Ninth Circuit to fully scrap a California law banning brand pharmaceutical companies from paying to delay generics competition, in a brief targeting both the law's in-state features upheld by a district court and the extraterritorial reach the state wants revived.

  • August 25, 2025

    AbbVie Nabs Depression Drug From Gilgamesh In $1.2B Deal

    Covington & Burling LLP-advised biotech company AbbVie on Monday announced plans to acquire Ropes & Gray LLP-led Gilgamesh Pharmaceuticals' lead investigational candidate, which targets the treatment of patients with moderate to severe major depressive disorder, for up to $1.2 billion.

  • August 25, 2025

    Pfizer Says FDA Blocked Tumor Warnings For Depo-Provera

    Pfizer said Friday that plaintiffs' claims in the multidistrict litigation over a link between brain tumors and the hormonal contraceptive Depo-Provera are preempted by federal law because the drugmaker asked the U.S. Food and Drug Administration for permission to change the drug's label to add tumor warnings but was rejected.

  • August 22, 2025

    Texas, Fla. Want In On Abortion Medication Challenge

    Texas and Florida have asked a Lone Star State federal court to allow them to intervene in litigation challenging federal approvals for the abortion medication mifepristone, arguing that their interests may "no longer be adequately represented" by Missouri, Kansas and Idaho, which are currently leading the suit.

  • August 22, 2025

    USPTO Allows Discretionary Denials For 3-Year-Old Patents

    A top Patent Trial and Appeal Board judge Friday rejected challenges to GenghisComm Holdings LLC patents issued as recently as 2022, as part of the three discretionary review decisions issued over the last week. 

  • August 22, 2025

    Chicago Feds Create New Healthcare Fraud Section

    The U.S. attorney's office in Chicago announced Friday it has created a section within its Criminal Division dedicated solely to prosecuting healthcare fraud, which the U.S. Department of Justice has identified as a fraud enforcement priority.

  • August 22, 2025

    Altria Unit Says FDA Stonewalled On Flavored E-Cig Approvals

    A subsidiary of tobacco giant Altria has filed a new lawsuit in Louisiana federal court against U.S. health regulators it alleges unlawfully delayed processing the company's applications to market flavored e-cigarettes for almost three years.

  • August 22, 2025

    Ex-Pharma Exec Leaked Bankruptcy Deliberations, Suit Says

    BioCurity Pharmaceuticals Inc. and its advisers sued a former officer of the company, alleging that she broke a nondisclosure agreement to disparage the advisers and leak the company's bankruptcy deliberations to its shareholders.

  • August 22, 2025

    Supplement Co. Says Insurer Failed To Pay $2.1M Claim

    The parent company of sports nutrition and supplement website Bodybuilding.com told an Idaho federal court that a Berkley unit failed to fully pay for property damage and business income loss after a water pipe burst at the Boise-based data center hosting the website's servers.

Expert Analysis

  • AG Watch: Texas Embraces The MAHA Movement

    Author Photo

    Attorneys at Kelley Drye examine Texas Attorney General Ken Paxton's actions related to the federal Make America Healthy Again movement, and how these actions hinge on representations or omissions by the target companies as opposed to specific analyses of the potential health risks.

  • Opinion

    Bar Exam Reform Must Expand Beyond A Single Updated Test

    Author Photo

    Recently released information about the National Conference of Bar Examiners’ new NextGen Uniform Bar Exam highlights why a single test is not ideal for measuring newly licensed lawyers’ competency, demonstrating the need for collaborative development, implementation and reform processes, says Gregory Bordelon at Suffolk University.

  • The Patent Eligibility Eras Tour: 11 Years Of Post-Alice Tumult

    Author Photo

    A survey of recent twists and turns in patent eligibility law highlights the confusion created by the U.S. Supreme Court's 2014 Alice decision and reveals that the continually shifting standards have begun to diverge in fundamental ways between the Federal Circuit and the U.S. Patent and Trademark Office, says Michael Shepherd at Fish & Richardson.

  • Location Data And Online Tracking Trends To Watch

    Author Photo

    Regulators and class action plaintiffs are increasingly targeting companies' use of online tracking technologies and geolocation data in both privacy enforcement and litigation, so organizations should view compliance as a dynamic, cross-functional responsibility as scrutiny becomes increasingly aggressive and multifaceted, say attorneys at Arnold & Porter.

  • A Simple Way Courts Can Help Attys Avoid AI Hallucinations

    Author Photo

    As attorneys increasingly rely on generative artificial intelligence for legal research, courts should consider expanding online quality control programs to flag potential hallucinations — permitting counsel to correct mistakes and sparing judges the burden of imposing sanctions, say attorneys at Lankler Siffert & Wohl and Connors.

  • DOJ Consumer Branch's End Leaves FDA Litigation Questions

    Author Photo

    With the dissolution of the U.S. Department of Justice's Consumer Protection Branch set to occur by Sept. 30, companies must carefully monitor how responsibility is reallocated for civil and criminal enforcement cases related to products regulated by the U.S. Food and Drug Administration, say attorneys at Foley & Lardner.

  • The Evolving Legal Landscape For THC-Infused Beverages

    Author Photo

    A recent Eighth Circuit ruling, holding that states may restrict the sale of intoxicating hemp-derived products without violating federal law, combined with ongoing regulatory uncertainty at both the federal and state levels, could alter the trajectory of the THC-infused beverage market, say attorneys at Pashman Stein.

  • Series

    Creating Botanical Art Makes Me A Better Lawyer

    Author Photo

    Pressing and framing plants that I grow has shown me that pursuing an endeavor that brings you joy can lead to surprising benefits for a legal career, including mental clarity, perspective and even a bit of humility, says Douglas Selph at Morris Manning.

  • Opinion

    The Legal Education Status Quo Is No Longer Tenable

    Author Photo

    As underscored by the fallout from California’s February bar exam, legal education and licensure are tethered to outdated systems, and the industry must implement several key reforms to remain relevant and responsive to 21st century legal needs, says Matthew Nehmer at The Colleges of Law.

  • 2nd Circ. Reinforces Consensus On Vacating Foreign Awards

    Author Photo

    In Molecular Dynamics v. Spectrum Dynamics Medical, the Second Circuit recently affirmed that federal district courts do not possess subject matter jurisdiction to vacate foreign arbitral awards, strengthening this consensus across the circuits most active in recognition and enforcement actions, says Ed Mullins at Reed Smith.

  • E-Discovery Quarterly: Rulings On Relevance Redactions

    Author Photo

    In recent cases addressing redactions that parties sought to apply based on the relevance of information — as opposed to considerations of privilege — courts have generally limited a party’s ability to withhold nonresponsive or irrelevant material, providing a few lessons for discovery strategy, say attorneys at Sidley.

  • How DOJ's New Data Security Rules Leave HIPAA In The Dust

    Author Photo

    The U.S. Department of Justice's recently effective data security requirements carry profound implications for how healthcare providers collect, store, share and use data — and approach vendor oversight — that go far beyond the Health Insurance Portability and Accountability Act, say attorneys at Nelson Mullins.

  • Opinion

    Section 1983 Has Promise After End Of Nationwide Injunctions

    Author Photo

    After the U.S. Supreme Court recently struck down the practice of nationwide injunctions in Trump v. Casa, Section 1983 civil rights suits can provide a better pathway to hold the government accountable — but this will require reforms to qualified immunity, says Marc Levin at the Council on Criminal Justice.

  • Trump's 2nd Term Puts Merger Remedies Back On The Table

    Author Photo

    In contrast with the Biden administration, the second Trump administration has signaled a renewed willingness to resolve merger enforcement concerns through remedies from the outset, particularly when the proposed fix is structural, clearly addresses the harm and does not require burdensome oversight, say attorneys at Cooley.

  • Patent Ambiguity Persists After Justices Nix Eligibility Appeal

    Author Photo

    The Supreme Court recently declined to revisit the contentious framework governing patent eligibility by denying certiorari in Audio Evolution Diagnostics v. U.S., suggesting a necessary recalibration of both patent application and litigation strategies, say attorneys at Skadden.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.